PI3Kp110-, Src-, FAK-dependent and DOCK2-independent migration and invasion of CXCL13-stimulated prostate cancer cells

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  El Haibi, Christelle P ^a   Sharma, Praveen K ^b   Singh, Rajesh ^c   Johnson, Paul R ^b   Suttles, Jill ^b   Singh, Shailesh ^c   Lillard Jr, James W ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b University of Louisville School of Medicine   (United States)

^c MOREHOUSE SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR5; CXCL13 CHEMOKINE; DEDICATOR OF CYTOKINESIS 2; FOCAL ADHESION KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE P110ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE P110BETA; PHOSPHATIDYLINOSITOL 3 KINASE P110DELTA; PHOSPHATIDYLINOSITOL 3 KINASE P110GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE P85ALPHA; PROTEIN TYROSINE KINASE; REGULATOR PROTEIN; UNCLASSIFIED DRUG; DOCK2 PROTEIN, HUMAN; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; FOCAL ADHESION KINASE 1; GUANINE NUCLEOTIDE EXCHANGE FACTOR; PTK2 PROTEIN, HUMAN;

ARTICLE; CANCER CELL; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL STRAIN LNCAP; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; CELL MOTION; ENZYME LINKED IMMUNOSORBENT ASSAY; MALE; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; SIGNAL TRANSDUCTION; TUMOR CELL LINE; WESTERN BLOTTING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MOVEMENT; CHEMOKINE CXCL13; CHEMOKINE CXCL5; ENZYME ACTIVATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FOCAL ADHESION KINASE 1; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HUMANS; MALE; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES;

EID: 77951066411     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-85     Document Type: Article

References (57)

1. Damber J-E, Aus G. Prostate cancer. Lancet 2008, 371:1710-1721. 10.1016/S0140-6736(08)60729-1, 18486743.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun M. Cancer Statistics. CA: A Cancer Journal for Clinicians 2008, 58:71-96. 10.3322/CA.2007.0010, 18287387.
3. Walczak JR, Carducci MA. Prostate Cancer: A Practical Approach to Current Management of Recurrent Disease. Mayo Clin Proc 2007, 82:243-249. 10.4065/82.2.243, 17290734.
4. Carlin BI, Andriole GL. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer 2000, 88:2989-2994. 10.1002/1097-0142(20000615)88:12+<2989::AID-CNCR14>3.0.CO;2-Q, 10898342.
5. Cher ML. Mechanisms governing bone metastasis in prostate cancer. Current Opinion in Urology 2001, 11:483-488. 10.1097/00042307-200109000-00006, 11493769.
6. Clark PE, Torti FM, Clark PE, Torti FM. Prostate cancer and bone metastases: medical treatment. Clin Orthop 2003, S148-157.
7. Clines GA, Guise TA, Clines GA, Guise TA. Molecular mechanisms and treatment of bone metastasis. Expert Reviews in Molecular Medicine 2008, 10:e7. 10.1017/S1462399408000616, 18321396.
8. Kingsley LA, Fournier PG, Chirgwin JM, Guise TA, Kingsley LA, Fournier PGJ, Chirgwin JM, Guise TA. Molecular biology of bone metastasis. Molecular Cancer Therapeutics 2007, 6:2609-2617. 10.1158/1535-7163.MCT-07-0234, 17938257.
9. Morrissey C, Vessella RL, Morrissey C, Vessella RL. The role of tumor microenvironment in prostate cancer bone metastasis. J Cell Biochem 2007, 101:873-886. 10.1002/jcb.21214, 17387734.
10. Vicari AP, Caux C, Vicari AP, Caux C. Chemokines in cancer. Cytokine Growth Factor Rev 2002, 13:143-154. 10.1016/S1359-6101(01)00033-8, 11900990.
11. Opdenakker G, Van Damme J, Opdenakker G, Van Damme J. The countercurrent principle in invasion and metastasis of cancer cells. Recent insights on the roles of chemokines. Int J Dev Biol 2004, 48:519-527. 10.1387/ijdb.041796go, 15349826.
12. Singh S, Singh UP, Grizzle WE, Lillard JW. CXCL12-CXCR4 interactions modulate prostate cancer cell migration, metalloproteinase expression and invasion. Lab Invest 2004, 84:1666-1676. 10.1038/labinvest.3700181, 15467730.
13. Albert Z. Chemokines and cancer. Int J Cancer 2006, 119:2026-2029. 10.1002/ijc.22024, 16671092.
14. Arya M, Patel HR, Williamson M, Patel HRH. Chemokines: key players in cancer. Curr Med Res Opin 2003, 19:557-564. 10.1185/030079903125002216, 14594528.
15. Vandercappellen J, Van Damme J, Struyf S. The role of CXC chemokines and their receptors in cancer. Cancer Lett 2008, 267:226-244. 10.1016/j.canlet.2008.04.050, 18579287.
16. Singh S, Singh R, Singh UP, Rai SN, Novakovic KR, Chung LW, Didier PJ, Grizzle WE, Lillard JW. Clinical and biological significance of CXCR5 expressed by prostate cancer specimens and cell lines. Int J Cancer 2009, 125:2288-2295. 10.1002/ijc.24574, 19610059.
17. Bonfil RD, Chinni S, Fridman R, Kim HR, Cher ML, Bonfil RD, Chinni S, Fridman R, Kim H-R, Cher ML. Proteases, growth factors, chemokines, and the microenvironment in prostate cancer bone metastasis. Urologic Oncology 2007, 25:407-411.
18. Singh S, Singh R, Sharma PK, Singh UP, Rai SN, Chung LWK, Cooper CR, Novakovic KR, Grizzle WE, Lillard JW. Serum CXCL13 positively correlates with prostatic disease, prostate-specific antigen and mediates prostate cancer cell invasion, integrin clustering and cell adhesion. Cancer Lett 2009, 283:29-35. 10.1016/j.canlet.2009.03.022, 19375853.
19. Lisignoli G, Toneguzzi S, Piacentini A, Cattini L, Lenti A, Tschon M, Cristino S, Grassi F, Facchini A, Lisignoli G, et al. Human osteoblasts express functional CXC chemokine receptors 3 and 5: activation by their ligands, CXCL10 and CXCL13, significantly induces alkaline phosphatase and beta-N-acetylhexosaminidase release. J Cell Physiol 2003, 194:71-79. 10.1002/jcp.10188, 12447991.
20. Maitland NJ, Macintosh CA, Hall J, Sharrard M, Quinn G, Lang S. In vitro models to study cellular differentiation and function in human prostate cancers. Radiat Res 2001, 155:133-142. 10.1667/0033-7587(2001)155[0133:IVMTSC]2.0.CO;2, 11121225.
21. Mitchell S, Abel P, Ware M, Stamp G, Lalani E. Phenotypic and genotypic characterization of commonly used human prostatic cell lines. BJU Int 2000, 85:932-944. 10.1046/j.1464-410x.2000.00606.x, 10792179.
22. Curnock AP, Logan MK, Ward SG. Chemokine signalling: pivoting around multiple phosphoinositide 3-kinases. Immunology 2002, 105:125-136. 10.1046/j.1365-2567.2002.01345.x, 1782650, 11872087.
23. Curnock AP, Sotsios Y, Ward SG, Curnock AP, Sotsios Y, Ward SG. Assessing the role of multiple phosphoinositide 3-kinases in chemokine signaling: use of dominant negative mutants controlled by a tetracycline-regulated gene expression system. Methods Mol Biol 2004, 239:211-222.
24. Daaka Y, Daaka Y. G proteins in cancer: the prostate cancer paradigm. Science's Stke: Signal Transduction Knowledge Environment 2004, 216:re2.
25. Kakinuma T, Hwang ST, Kakinuma T, Hwang ST. Chemokines, chemokine receptors, and cancer metastasis. J Leukoc Biol 2006, 79:639-651. 10.1189/jlb.1105633, 16478915.
26. O'Hayre M, Salanga CL, Handel TM, Allen SJ, O'Hayre M, Salanga CL, Handel TM, Allen SJ. Chemokines and cancer: migration, intracellular signaling and intercellular communication in the microenvironment. Biochem J 2008, 409:635-649. 10.1042/BJ20071493, 18177271.
27. Sotsios Y, Ward SG. Phosphoinositide 3-kinase: a key biochemical signal for cell migration in response to chemokines. Immunol Rev 2000, 177:217. 10.1034/j.1600-065X.2000.17712.x, 11138779.
28. Cooney KA, Tsou HC, Petty EM, Miesfeldt S, Ping XL, Gruener AC, Peacocke M. Absence of PTEN germ-line mutations in men with a potential inherited predisposition to prostate cancer. Clin Cancer Res 1999, 5:1387-1391.
29. Fang J, Ding M, Yang L, Liu L-Z, Jiang B-H. PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis. Cell Signal 2007, 19:2487-2497. 10.1016/j.cellsig.2007.07.025, 2094004, 17826033.
30. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997, 275:1943-1947. 10.1126/science.275.5308.1943, 9072974.
31. Sanui T, Inayoshi A, Noda M, Iwata E, Stein JV, Sasazuki T, Y F. DOCK2 regulates Rac activation and cytoskeletal reorganization through interaction with ELMO1. Blood 2003, 102:2948-2950. 10.1182/blood-2003-01-0173, 12829596.
32. Chung CY, Lee S, Briscoe C, Ellsworth C, Firtel RA. Role of Rac in controlling the actin cytoskeleton and chemotaxis in motile cells. Proc Natl Acad Sci USA 2000, 97:5225-5230. 10.1073/pnas.97.10.5225, 25810, 10805781.
33. Fukui Y, Hashimoto O, Sanui T, Oono T, Koga H, Abe M, Inayoshi A, Noda M, Oike M, Shirai T, Sasazuki T. Hematopoietic cell-specific CDM family protein DOCK2 is essential for lymphocyte migration. Nature 2001, 412:826-831. 10.1038/35090591, 11518968.
34. Kunisaki Y, Nishikimi A, Tanaka Y, Takii R, Noda M, Inayoshi A, Watanabe K, Sanematsu F, Sasazuki T, Sasaki T, et al. DOCK2 is a Rac activator that regulates motility and polarity during neutrophil chemotaxis. J Cell Biol 2006, 174:647-652. 10.1083/jcb.200602142, 2064308, 16943182.
35. Nombela-Arrieta C, Lacalle RA, Montoya MC, Kunisaki Y, Megias D, Marques M, Carrera AC, Manes S, Fukui Y, Martinez AC, Stein JV. Differential requirements for DOCK2 and phosphoinositide-3-kinase gamma during T and B lymphocyte homing. Immunity 2004, 21:429-441. 10.1016/j.immuni.2004.07.012, 15357953.
36. Mitra SK, Schlaepfer DD, Mitra SK, Schlaepfer DD. Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol 2006, 18:516-523. 10.1016/j.ceb.2006.08.011, 16919435.
37. Parsons S, Parsons J. Src family kinases, key regulators of signal transduction. Oncogene 2004, 23:7906-7909. 10.1038/sj.onc.1208160, 15489908.
38. Piiper A, Zeuzem S. Receptor Tyrosine Kinases are Signaling Intermediates of G Protein-Coupled Receptors. In Curr Pharm Des 2004, 10:3539-3545. Bentham Science Publishers Ltd.
39. Johnson TR, Khandrika L, Kumar B, Venezia S, Koul S, Chandhoke R, Maroni P, Donohue R, Meacham RB, Koul HK. Focal Adhesion Kinase Controls Aggressive Phenotype of Androgen-Independent Prostate Cancer. Mol Cancer Res 2008, 6:1639-1648. 10.1158/1541-7786.MCR-08-0052, 18922979.
40. Cuevas BD, Lu Y, Mao M, Zhang J, LaPushin R, Siminovitch, Mills GB. Tyrosine phosphorylation of p85 relieves its inhibitory activity on phosphatidylinositol 3-kinase. J Biol Chem 2001, 276:27455-61. 10.1074/jbc.M100556200, 11337495.
41. May LT, Hill SJ, May LT, Hill SJ. ERK phosphorylation: spatial and temporal regulation by G protein-coupled receptors. Int J Biochem Cell Biol 2008, 40:2013-2017. 10.1016/j.biocel.2008.04.001, 18502166.
42. Cooper CR, Chay CH, Gendernalik JD, Lee HL, Bhatia J, Taichman RS, McCauley LK, Keller ET, Pienta KJ, Cooper CR, et al. Stromal factors involved in prostate carcinoma metastasis to bone. Cancer 2003, 97:739-747. 10.1002/cncr.11181, 12548571.
43. Cross NA, Papageorgiou M, Eaton CL. Bone marrow stromal cells promote growth and survival of prostate cancer cells. Biochem Soc Trans 2007, 35:698-700. 10.1042/BST0350692, 17635126.
44. Wu Z, McRoberts KS, Theodorescu D. The role of PTEN in prostate cancer cell tropism to the bone microenvironment. Carcinogenesis 2007, 28:1393-1400. 10.1093/carcin/bgm050, 17347137.
45. New D, Wong Y. Molecular mechanisms mediating the G protein-coupled receptor regulation of cell cycle progression. J Mol Signal 2007, 2:2. 10.1186/1750-2187-2-2, 1808056, 17319972.
46. Pierce K, Premont R, Lefkowitz R. Seven-transmembrane receptors. Nature Rev Mol Cell Biol 2002, 3:639-650.
47. Kojima K, Shimanuki M, Shikami M, Samudio IJ, Ruvolo V, Corn P, Hanaoka N, Konopleva M, Andreeff M, Nakakuma H. The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML. Leukemia 2008, 22:1728-1736. 10.1038/leu.2008.158, 18548093.
48. Prevo R, Deutsch E, Sampson O, Diplexcito J, Cengel K, Harper J, O'Neill P, McKenna WG, Patel S, Bernhard EJ, et al. Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity. Cancer Res 2008, 68:5915-5923. 10.1158/0008-5472.CAN-08-0757, 18632646.
49. Frazzetto M, Suphioglu C, Zhu J, Schmidt-Kittler O, Jennings IG, Cranmer SL, Jackson SP, Kinzler KW, Vogelstein B, Thompson PE, et al. Dissecting isoform selectivity of PI3K inhibitors: the role of non-conserved residues in the catalytic pocket. Biochem J 2008, 414:383-390. 10.1042/BJ20080512, 2820364, 18489260.
50. Straub A, Wendel HP, Dietz K, Schiebold D, Peter K, Schoenwaelder SM, Ziemer G, Straub A, Wendel HP, Dietz K, et al. Selective inhibition of the platelet phosphoinositide 3-kinase p110beta as promising new strategy for platelet protection during extracorporeal circulation. Thromb Haemost 2008, 99:609-615.
51. Zvelebil MJ, Waterfield MD, Shuttleworth SJ, Zvelebil MJ, Waterfield MD, Shuttleworth SJ. Structural analysis of PI3-kinase isoforms: identification of residues enabling selective inhibition by small molecule ATP-competitive inhibitors. Arch Biochem Biophys 2008, 477:404-410. 10.1016/j.abb.2008.06.024, 18647592.
52. Fougerat A, Gayral S, Gourdy P, Schambourg A, Ruckle T, Schwarz MK, Rommel C, Hirsch E, Arnal JF, Salles JP, et al. Genetic and pharmacological targeting of phosphoinositide 3-kinase-gamma reduces atherosclerosis and favors plaque stability by modulating inflammatory processes. Circulation 2008, 117:1310-1317. 10.1161/CIRCULATIONAHA.107.720466, 18268153.
53. Maus UA, Backi M, Winter C, Srivastava M, Schwarz MK, Ruckle T, Paton JC, Briles D, Mack M, Welte T, et al. Importance of phosphoinositide 3-kinase gamma in the host defense against pneumococcal infection. Am J Respir Crit Care Med 2007, 175:958-966. 10.1164/rccm.200610-1533OC, 17322108.
54. Price DT, Della Rocca G, Guo C, Ballo MS, Schwinn DA, Luttrell LM. Activation of extracellular signal-regulated kinase in human prostate cancer. J Urol 1999, 162:1537-1542. 10.1016/S0022-5347(05)68354-1, 10492251.
55. Moro L, Arbini AA, Yao JL, di Sant'Agnese PA, Marra E, Greco M, Moro L, Arbini AA, Yao JL, di Sant'Agnese PA, et al. Loss of BRCA2 promotes prostate cancer cell invasion through up-regulation of matrix metalloproteinase-9. Cancer Science 2008, 99:553-563. 10.1111/j.1349-7006.2007.00719.x, 18167127.
56. Fukui Y, Hashimoto O, Sanui T, Oono T, Koga H, Abe M, Inayoshi A, Noda M, Oike M, Shirai T, Sasazuki T. Haematopoietic cell-specific CDM family protein DOCK2 is essential for lymphocyte migration. Nature 2001, 412:826-831. 10.1038/35090591, 11518968.
57. Durand CA, Westendorf J, Tse KW, Gold MR, Durand CA, Westendorf J, Tse KWK, Gold MR. The Rap GTPases mediate CXCL13- and sphingosine1-phosphate-induced chemotaxis, adhesion, and Pyk2 tyrosine phosphorylation in B lymphocytes. Eur J Immunol 2006, 36:2235-2249. 10.1002/eji.200535004, 16821235.